1231930-37-2Relevant articles and documents
Hydrogen Evolution from Telescoped Miyaura Borylation and Suzuki Couplings Utilizing Diboron Reagents: Process Safety and Hazard Considerations
Merritt, Jeremy M.,Borkar, Indrakant,Buser, Jonas Y.,Brewer, Alison Campbell,Campos, Odilon,Fleming, Jeffrey,Hansen, Caoimhe,Humenik, Ashley,Jeffery, Stephen,Kokitkar, Prashant B.,Kolis, Stanley P.,Forst, Mindy B.,Lambertus, Gordon R.,Martinelli, Joseph R.,McCartan, Ciaran,Moursy, Hossam,Murphy, Donal,Murray, Michael M.,O'Donnell, Kevin,O'Sullivan, Rita,Richardson, Gary A.,Xia, Han
, p. 773 - 784 (2022)
The hazard assessment of a telescoped Miyaura borylation and Suzuki coupling reaction employing bis(pinacolato)diboron (BisPin), used in the developmental synthesis of an intermediate for abemaciclib, led to the observation of hydrogen being generated. Quantitative headspace GC and solution 11B NMR were used to show that the rapid decomposition of the excess BisPin from the borylation under the aqueous basic conditions of the Suzuki reaction was responsible for H2 generation. The moles of H2 observed were found equal to the BisPin excess, which is rationalized by mass balance and a stoichiometric reaction. The possible generation of the stoichiometric levels of H2 should be considered in hazard assessments of this class of reaction. Kinetic and process modeling was used to minimize the risk upon scale-up, and results for commercial manufacturing batches are presented, which showed good agreement with the lab scale data. Furthermore, the hydrogen evolution potentials of other common borylating agents including bisboronic acid (BBA) and pinacol borane were demonstrated.
A pyrimidine compound and its application
-
, (2022/01/12)
The present invention discloses a pyrimidine amine compound having a general formula I structure and its applications, the class of compounds belongs to the kinase CDK4, CDK6 and / or CDK9 inhibitors, can be more widely used in the treatment of a variety
CRYSTALLINE POLYMORPHS OF ABEMACICLIB
-
, (2019/06/11)
The present disclosure provides novel polymorphs of abemaciclib, solid dispersions of abemaciclib with pharmaceutical excipients, and processes for the preparation thereof. The disclosure further provides methods for preparing crystalline abemaciclib form I, amorphous abemaciclib, and methods for synthesizing abemaciclib.